F-18 labeled fluorodihydroxyphenylalanine (F-18 FDOPA) appears to find more cancer for patients with neuroendocrine tumors who have had negative conventional and somatostatin receptor scintigraphy, according to a study published Dec. 16 in the Journal of Nuclear Medicine. {read more here}